| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
The dogma for treatment of cancer has changed, with the cytotoxic drugs used
in chemotherapy regimes set to lose their dominance and be used alongside
targeted therapies that are being developed with the aim of more specifically
targeting cancer cells
Research and analysis highlights
In this comprehensive report covering targeted therapies in oncology,
BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors,
anti-angiogenic and vascular targeting agents, immunostimulators, antibodies
and vaccines in oncology. This extensive 550+ pages report compiles and
analyzes in parallel the progress concerning drug development and competitive
situation in the mentioned key oncology targeted therapy areas. The report
will not only provide a framework but also a careful identification and
evaluation of drug candidates, technologies and competitors. The number of
targeted therapy drugs has risen sharply, as have the number of targets. The
fiercest competition in oncology targeted therapy is pointed out and how
several big pharma companies are out hunting for promising technology and
drugs to complement their internal pipeline.
Scope of this report
- In-depth competitive landscape assessment of the targeted oncology market
place; Including more than 340 drugs and pharmaceutical companies
- Thorough review of six major targeting strategies in oncology: Apoptopic
agents, Protein kinase inhibitors, Anti-angiogenic and vascular targeting
agents, Immunostimulators, Antibodies and Vaccines
- Progress analysis of major cancer indications for respective targeting
strategy, including players, drugs, clinical progress and pitfalls
- Includes more than 120 Tables, 60 Boxes and close to 40 Figures
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization
of six major targeting strategies in oncology
- Assess opportunities and risks for the continued development of targeting
agents in major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions
in oncology drug development
TABLE OF CONTENTS
1 Executive Summary
2 Table of Contents
- 2.1 List of Boxes
- 2.2 List of Figures
- 2.3 List of Tables
3 Methodology
4 Introduction to Apoptosis in Oncology
5 Apoptosis Competitive Landscape in Oncology
- 5.1 Countries & Players: Who are In the Lead?
- 5.1.1 Top 10 Players Dominate The Developmental Pipeline
- 5.2 Deals & Alliances in Apoptosis Drug Development
- 5.2.1 Review of Deals and Alliances Initiated in 2006
- 5.2.2 Review of Deals and Alliances Initiated in 2005
- 5.2.3 Review of Deals and Alliances Initiated in 2004
- 5.2.4 Review of Deals and Alliances Initiated in 2003
- 5.2.5 Review of Deals and Alliances Initiated in 2002
- 5.2.6 Review of Deals and Alliances Initiated in 2001
6 Approved Apoptopic Cancer Drugs: Performance
7 Target Analysis in Apoptosis
- 7.1 Targets of Late Stage Apoptopic Drugs in Development
- 7.1.1 B-cell CLL/lymphoma 2
- 7.1.2 Caspase 3
- 7.1.3 CD4 molecule
- 7.1.4 Cytosolic ovarian carcinoma antigen 1
- 7.1.5 Eukaryotic translation elongation factor 2
- 7.1.6 Farnesyltransferase, CAAX box, alpha
- 7.1.7 Fc fragment of IgE
- 7.1.8 Histone deacetylase 1
- 7.1.9 Histone deacetylase 2
- 7.1.10 Interleukin 13 receptor, alpha 1
- 7.1.11 Phosphodiesterase 2A, cGMP-stimulated
- 7.1.12 Phosphodiesterase 5A, cGMP-specific
- 7.1.13 Protein kinase C, beta 1
- 7.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
- 7.1.15 Topoisomerase (DNA) I
- 7.1.16 Topoisomerase (DNA) II alpha
- 7.1.17 Tubulin, beta polypeptide
- 7.1.18 p53 protein
- 7.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
- 7.2.1 Targets in Breast Cancer
- 7.2.2 Targets in Leukemia
- 7.2.3 Targets in Lung Cancer
- 7.2.4 Targets in Lymphoma
- 7.2.5 Targets in Prostate Cancer
8 Apoptopic Drugs in Development: By Major Indications
- 8.1 General Drug Developmental Overview
- 8.1.1 Apoptopic Drugs in Phase III Clinical Development
- 8.1.2 Failed Apoptopic Drugs in Oncology
- 8.2 Progress Analysis - Breast Cancer
- 8.2.1 Phase I Clinical Development
- 8.2.2 Phase II Clinical Development
- 8.2.3 Phase III Clinical Development
- 8.3 Progress Analysis - Leukemia
- 8.3.1 Phase I Clinical Development
- 8.3.2 Phase II Clinical Development
- 8.3.3 Phase III Clinical Development
- 8.4 Progress Analysis - Lung Cancer
- 8.4.1 Phase I Clinical Development
- 8.4.2 Phase II Clinical Development
- 8.4.3 Phase III Clinical Development
- 8.5 Progress Analysis - Lymphoma
- 8.5.1 Phase I Clinical Development
- 8.5.2 Phase II Clinical Development
- 8.5.3 Phase III Clinical Development
- 8.6 Progress Analysis - Prostate Cancer
- 8.6.1 Phase I Clinical Development
- 8.6.2 Phase II Clinical Development
- 8.6.3 Phase III Clinical Development
9 Protein Kinase Inhibitors
- 9.1 Rationale for Development of Kinase Inhibitors in Oncology
- 9.2 Protein Kinase Targets - A Growing Family
- 9.3 Challenges in Protein Kinase Drug Discovery
- 9.3.1 Enabling Structure-Based Drug Design is the Key
- 9.3.2 Specific Kinase Inhibitors without Kinase Profiling?
- 9.4 Drugs according to Target
- 9.4.1 Cyclin-dependent Kinase Target Inhibitors
- 9.4.2 Aurora Kinase Target Inhibitors
- 9.4.3 Cell Cycle Checkpoint Target Controls Inhibitors
- 9.4.4 Tyrosine Kinase Receptor Inhibitors
- 9.4.5 Other Serine/Threonine Kinase Target Inhibitors
- 9.5 Dual or Multiple Kinase Inhibitor Analysis
- 9.5.1 Presentation of Drugs Targeting A to F Kinases
- 9.5.2 Presentation of Drugs Targeting G to T Kinases
- 9.6 Targets According to Indication
- 9.6.1 Breast Cancer
- 9.6.2 Prostate Cancer: What Cannot be Found in the 'Groins'?
- 9.6.3 Lung Cancer: A Need for Improved Survival Rates
- 9.6.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are
Others
- 9.6.5 Leukemia: Show Me the Power of PKI
- 9.6.6 Melanoma
- 9.6.7 Lymphoma: We Are In
- 9.7 Growing Competition in the Field
- 9.8 Big Pharma Outlook: The Race is On
- 9.8.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
- 9.8.2 AstraZeneca - Wheeling and Dealing
- 9.8.3 Pfizer's Long Look at OSI Pharmaceuticals
- 9.8.4 GlaxoSmithKline Gains Momentum
- 9.9 Strategic Deals Creating Competitive Edge
- 9.9.1 Mergers
- 9.9.2 Astex - the PKI Switchboard
- 9.9.3 Big Pharma's Darling
- 9.10 Current Protein Kinase Inhibitors in Therapy
- 9.10.1 Mechanism, Target and Developmental History
- 9.10.2 Approvals: Indications & Markets
- 9.11 Protein Kinase Inhibitors in Drug Development - A Progress Analysis
- 9.11.1 Progress Analysis - Breast Cancer
- 9.11.2 Progress Analysis - Prostate Cancer
- 9.11.3 Progress Analysis - Lung Cancer
- 9.11.4 Progress Analysis - Colorectal Cancer
- 9.11.5 Progress Analysis - Leukemia
- 9.11.6 Progress Analysis - Melanoma
- 9.11.7 Progress Analysis - Lymphoma
10 Anti-Angiogenesis & Vascular Targeting
- 10.1 Neoplastic Angiogenesis & Tumor Vasculature
- 10.1.1 Tumor Vasculature
- 10.1.2 The Current Model of Sprouting Angiogenesis
- 10.2 Main Angiogenic Factors
- 10.2.1 Vascular Endothelial Growth Factor
- 10.2.2 The Angiopoietins and Platelet Derived Growth Factor
- 10.2.3 Integrins in Angiogenesis
- 10.2.4 Inhibitors of Angiogenesis
- 10.3 Vascular Targeting Agents
- 10.4 Vascular Disruptive Agents
- 10.5 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in
Oncology
- 10.6 Countries & Players: Who are In the Lead?
- 10.6.1 Top 10 Players Dominate The Developmental Pipeline
- 10.7 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
- 10.7.1 Review of Deals and Alliances Initiated in 2005
- 10.7.2 Review of Deals and Alliances Initiated in 2004
- 10.7.3 Review of Deals and Alliances Initiated in 2003
- 10.8 Approved Anti-Angiogenic Cancer Drugs: Performance
- 10.9 Target Analysis in Anti-Angiogenesis and Vascular Targeting
- 10.10 Targets of Late Stage Anti-Angiogenic Drugs in Development
- 10.10.1 Drugs with Epidermal Growth Factor Receptor as a Target
- 10.10.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
- 10.10.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
- 10.10.4 Drugs with Kinase Insert Domain Receptor as a Target
- 10.10.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
- 10.10.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
- 10.10.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha
Polypeptide as a Target
- 10.10.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a
Target
- 10.10.9 Drugs with Protein Kinase C, beta 1 as a Target
- 10.10.10 Drugs with Ret Proto-Oncogene as a Target
- 10.10.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral
Oncogene Homolog as a Target
- 10.10.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as
a Target
- 10.10.13 Drugs with Vascular Endothelial Growth Factor as a Target
- 10.11 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer
Indications
- 10.11.1 Targets in Breast Cancer
- 10.11.2 Targets in Colorectal Cancer
- 10.11.3 Targets in Lung Cancer
- 10.11.4 Targets in Prostate Cancer
- 10.11.5 Targets in Renal Cancer
- 10.12 Anti-angiongenesis and Vascular Targeting Drugs in Development: By
Major Indications
- 10.13 General Drug Developmental Overview
- 10.14 Progress Analysis - Breast Cancer
- 10.14.1 Phase I Clinical Development
- 10.14.2 Phase II Clinical Development
- 10.14.3 Phase III Clinical Development
- 10.15 Progress Analysis - Colorectal Cancer
- 10.15.1 Phase I Clinical Development
- 10.15.2 Phase II Clinical Development
- 10.15.3 Phase III Clinical Development
- 10.16 Progress Analysis - Lung Cancer
- 10.16.1 Phase I Clinical Development
- 10.16.2 Phase II Clinical Development
- 10.16.3 Phase III Clinical Development
- 10.17 Progress Analysis - Prostate Cancer
- 10.17.1 Phase I Clinical Development
- 10.17.2 Phase II Clinical Development
- 10.17.3 Phase III Clinical Development
- 10.18 Progress Analysis - Renal Cancer
- 10.18.1 Phase I Clinical Development
- 10.18.2 Phase II Clinical Development
- 10.18.3 Phase III Clinical Development
11 Immunotherapy in Oncology
- 11.1 Vaccine Strategies: Challenges & Opportunities
- 11.2 Key Antibody Developmental Strategies
12 Competitive Landscape in Cancer Vaccines
- 12.1 Countries & Players: Who are In the Lead?
- 12.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not
Included!
- 12.1.2 Approved Cancer Vaccine Drugs: Performance
- 12.2 Deals & Alliances in Cancer Vaccines
- 12.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
- 12.2.2 Deals in Prostate Cancer
- 12.2.3 Deals in Breast Cancer
- 12.2.4 Deals in Leukemia & Lymphoma
- 12.2.5 Drug Delivery Deals in Cancer Vaccines
- 12.2.6 Adjuvant Deals
13 Antibody Deals on the Rise
- 13.1 Antibody Deals in Phase III
- 13.1.1 Deal Situation: MDX 010
- 13.1.2 Deal Situation: WX G250
- 13.1.3 Deal Situation: Zanolimumab
- 13.2 Antibody Deals in Phase II
- 13.2.1 Deal Situation: Mapatumumab
- 13.2.2 Deal Situation: GCR 3888
- 13.2.3 Deal Situation: MDX 070
- 13.2.4 Deal Situation: CDP 860
- 13.2.5 Deal Situation: Tru-Scint OV
- 13.2.6 Deal Situation: SC 1
- 13.2.7 Deal Situation: PRO 70769
- 13.2.8 Deal Situation: XR 303
- 13.2.9 Deal Situation: HumaRAD-HN
14 Tumor Antigens
- 14.1 Tumor Antigens: General Comments
- 14.2 Antigen Discovery
- 14.2.1 Classical Immunology Approach
- 14.2.2 The Reverse Immunology Approach
- 14.2.3 Company Platforms
- 14.3 Specific Antigen Processing Technologies Increasing Antigen
Presentation
15 Immunomodulators & Adjuvants in Cancer Vaccines
- 15.1 Overview
- 15.2 Cytokines
- 15.2.1 Vaccines in Combination with Interleukin-2
- 15.2.2 Tumor Necrosis Factor
- 15.2.3 Interferons
- 15.3 Adjuvants
- 15.4 Other Immunomodulating Strategies
- 15.4.1 An Immune Response Modifying Protein
- 15.4.2 Immunostimulatory DNA
- 15.4.3 Ex Vivo Stimulated Immune Cells
- 15.4.4 Fusion Protein Gain Potent Immune Response
- 15.4.5 Macrophage and Natural Killer Cells Activation
- 15.4.6 Selective Suppression of the Immune System to An Antigen
- 15.4.7 TAP Technology
16 Cancer Vaccine Delivery
- 16.1 Viral Delivery
- 16.1.1 Introduction
- 16.1.2 Viral Constructs Put into Use
- 16.2 Bacterias
- 16.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
- 16.3.1 Introduction
- 16.3.2 Cell Therapy Strategies
- 16.4 Synthetic Delivery Systems & Strategies
- 16.4.1 Introduction
- 16.4.2 Biotransport™
- 16.4.3 Biotype®vector
- 16.4.4 DNAVax Gene Delivery System
- 16.4.5 FusitAb™
- 16.4.6 GeneDrug™
- 16.4.7 Molecular Conjugates
- 16.4.8 Naked DNA Delivery
- 16.4.9 PVLP Technology
- 16.4.10 Sphingosomal Drug Delivery Technology
- 16.4.11 STEALTH
- 16.4.12 Failed Liposomal Systems
17 New Approaches in Antibody Delivery and Design - The Next Generation
- 17.1 How to Make Them Smaller and Different?
- 17.2 Biomaterials in Sustained Delivery Applications
- 17.3 Gene delivery - the Future?
- 17.3.1 Delivery Vehicles for DNA
- 17.3.2 Gene Delivery in Commercialization
18 Cancer Vaccines in Development: By Major Indications
- 18.1 General Oncology Overview
- 18.2 Progress Analysis - Melanoma
- 18.3 Progress Analysis - Breast Cancer
- 18.4 Progress Analysis - Prostate Cancer
- 18.5 Progress Analysis - Lung Cancer
- 18.6 Progress Analysis - Colorectal Cancer
- 18.7 Progress Analysis - Cervical Cancer
19 Antibodies in Clinical Development
- 19.1.1 Prostate Cancer Therapeutics
- 19.1.2 Breast Cancer Therapeutics
- 19.1.3 Colorectal Cancer Therapeutics
- 19.1.4 Melanoma Therapeutics
- 19.1.5 Hematological Cancers Therapeutics
- 19.2 Antibodies in Phase III Clinical Development
- 19.2.1 Progress Analysis: IGN 101
- 19.2.2 Progress Analysis: MDX 010
- 19.2.3 Progress Analysis: ONYVAX 105
- 19.2.4 Progress Analysis: Ovarex
- 19.2.5 Progress Analysis: Panitumumab
- 19.2.6 Progress Analysis: RENCAREX
- 19.2.7 Progress Analysis: Nimotuzumab
- 19.2.8 Progress Analysis: TransMID
- 19.2.9 Progress Analysis: Lintuzumab
- 19.2.10 Progress Analysis: Zanolimumab
- 19.3 Antibodies in Phase II Clinical Development
- 19.3.1 Progress Analysis: ABT-510
- 19.3.2 Progress Analysis: BB 10901
- 19.3.3 Progress Analysis: CP 675206
- 19.3.4 Progress Analysis: CNTO-328
- 19.3.5 Progress Analysis: Ecromeximab
- 19.3.6 Progress Analysis: EMD 273063
- 19.3.7 Progress Analysis: WX-G250RIT
- 19.3.8 Progress Analysis: HGS-ETR1
- 19.3.9 Progress Analysis: HuMax-CD20
- 19.3.10 Progress Analysis: HuMax-EGFr
- 19.3.11 Progress Analysis: Galiximab
- 19.3.12 Progress Analysis: PROXINIUM
- 19.3.13 Progress Analysis: RAV12
- 19.3.14 Progress Analysis: SGN-15
- 19.3.15 Progress Analysis: SGN-30
- 19.3.16 Progression Analysis: VEGF-Trap
- 19.3.17 Progress Analysis: MEDI 522
- 19.3.18 Progress Analysis: Volociximab
20 Disclaimer
21 Appendix I: Complete List of Apoptopic Drugs in Development in Oncology
22 Appendix II: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology
23 Company Index
24 Drug Index
List of Boxes
- Box 1: Business & Market - PXD-101
- Box 2: Business & Market - MG-98
- Box 3: Business & Market - VX-680
- Box 4: Business & Market - Ceflatonin
- Box 5: Business & Market - Oblimersen sodium
- Box 6: Business & Market - motexafin gadolinium
- Box 7: Business & Market - 1D09C3
- Box 8: Business & Market - PCK-3145
- Box 9: Business & Market - ME-2
- Box 10: The Power of Ambit's Kinase Profiling
- Box 11: Summary Terms of the Exelixis Transaction
- Box 12: Nexavar's Clinical Data That Lead To Its EMEA Approval Myeloma
- Box 13: Thalomid Delays Time to Disease Progression in Newly Diagnosed
Multiple Myeloma
- Box 14: Strong Clinical Data Suggests Approval to Market Avastin For The
Treatment of Both Breast Cancer and NSCLC
- Box 15: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic
Cancer
- Box 16: Business & Market - Cilengitide
- Box 17: Business & Market - Exherin
- Box 18: Business & Market - WX-UK1
- Box 19: Business & Market - Combretastatin A-4 phosphate
- Box 20: Business & Market - GCS-100LE
- Box 21: Business & Market - PTK/ZK
- Box 22: Business & Market - AS-1404
- Box 23: Business & Market - Phosphomannopentaose sulfate
- Box 24: Business & Market - Squalamine
- Box 25: Business & Market - talactoferrin alfa
- Box 26: Business & Market - ZD-6474
- Box 27: Business & Market - AP-23573
- Box 28: Business & Market - Volociximab
- Box 29: Business & Market - XL-999
- Box 30: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
- Box 31: M-VAX - Business & Market Bakground
- Box 32: Gardasil: Business & Market Background
- Box 33: The Principal Terms of Deal between AstraZeneca and Cambridge
Antibody Technology
- Box 34: TNF in Cancer Treatments
- Box 35: Marrion's Drug Delivery Technology
- Box 36: Quick Facts - IGN 101
- Box 37: Quick Facts - MDX 010
- Box 38: Quick Facts - ONYVAX 105
- Box 39: Quick Facts - Ovarex
- Box 40: Quick Facts - Panitumumab
- Box 41: Quick Facts - RENCARNEX
- Box 42: Quick Facts - Nimotuzumab
- Box 43: Quick Facts - RENCARNEX
- Box 44: Quick Facts - Lintuzumab
- Box 45: Quick Facts - Zanolimumab
- Box 46: Quick Facts - ABT-510
- Box 47: Quick Facts - BB 10901
- Box 48: Quick Facts - CP-675206
- Box 49: Quick Facts - CNTO-328
- Box 50: Quick Facts - Ecromeximab
- Box 51: Quick Facts - EMD-273063
- Box 52: Quick Facts - WX-G250RIT
- Box 53: Quick Facts - HGS-ETR1
- Box 54: Quick Facts - HuMax-CD20
- Box 55: Quick Facts - HuMax-EGFr
- Box 56: Quick Facts - Galiximab
- Box 57: Quick Facts - PROXINIUM
- Box 58: Quick Facts - RAV12
- Box 59: Quick Facts -SGN-15
- Box 60: Quick Facts -SGN-30
- Box 61: Quick Facts - VEGF-Trap
- Box 62: Quick Facts - MEDI 522
- Box 63: Quick Facts - Volociximab
List of Figures
- Figure 1: Top 5 Countries in Apoptopic Cancer Research
- Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug
Development
- Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
- Figure 4: Distribution of ApoptopicTrials in Breast Cancer
- Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
- Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
- Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
- Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
- Figure 9: Top 10 PKI Drug Developing Companies
- Figure 10: Clinical Trial Distribution in Breast Cancer for PKI Drugs
- Figure 11: Clinical Trial Distribution in Prostate Cancer for PKI Drugs
- Figure 12: Clinical Trial Distribution in Lung Cancer for PKI Drugs
- Figure 13: Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
- Figure 14: Clinical Trial Distribution in Leukemia for PKI Drugs
- Figure 15: Clinical Trial Distribution in Melanoma for PKI Drugs
- Figure 16: Clinical Trial Distribution in Lymphoma for PKI Drugs
- Figure 17: Establishment of Blood Supply to Tumors
- Figure 18: Sprouting Angiogenesis
- Figure 19: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting
Research
- Figure 20: Top 10 Companies' Clinical Trial Progress in Anti-Angiogenesis
and Vascular Targeting
- Figure 21: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
2001-2005
- Figure 22: Annual Sales of Avastin on US and Non US Markets
- Figure 23: Trial Distribution of the Entire Anti-Angiogenic and Vascular
Target Agent Field in Oncology
- Figure 24: Distribution of Anti-Angiogensis & Vascular Targeting Trials in
Breast Cancer
- Figure 25: Distribution of Anti-Angiogensis & Vascular Targeting Trials in
Colorectal
- Figure 26: Distribution of Anti-Angiogensis & Vascular Targeting Trials in
Lung Cancer
- Figure 27: Distribution of Anti-Angiogensis & Vascular Targeting Trials in
Prostate Cancer
- Figure 28: Distribution of Anti-Angiogensis & Vascular Targeting Trials in
Renal Cancer
- Figure 29: Top 10 Countries in Cancer Vaccine Research
- Figure 30: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
- Figure 31: 2003-2005 Deals & Alliances in Cancer Vaccine
- Figure 32: Distribution of Cancer Vaccine Trials in Melanoma
- Figure 33: Distribution of Cancer Vaccine Trials in Breast Cancer
- Figure 34: Distribution of Cancer Vaccine Trials in Prostate Cancer
- Figure 35: Distribution of Cancer Vaccine Trials in Lung Cancer
- Figure 36: Distribution of Cancer Vaccine Trials in Colorectal Cancer
- Figure 37: Distribution of Cancer Vaccine Trials in Cervical Cancer
List of Tables
- Table 1: Top 10's Apoptopic Pipeline Drugs
- Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
- Table 3: Companies with Apoptopic Cancer Drugs on the Market
- Table 4: List of 120 Known Targets in Apoptosis Drug Development
- Table 5: Known Targets of Late Stage Apoptopic Drugs Development
- Table 6: Drugs with Bcl-2 as a Target
- Table 7: Drugs with Casp-3 as a Target
- Table 8: Drugs with CD4 molecule as a Target
- Table 9: Drugs with Cova-1 as a Target
- Table 10: Drugs with Eef-2 as a Target
- Table 11: Drugs with Fnta as a Target
- Table 12: Drugs with Fcer-2 as a Target
- Table 13: Drugs with Hdac-1 as a Target
- Table 14: Drugs with Hdac-2 as a Target
- Table 15: Drugs with IL13-RA1 as a Target
- Table 16: Drugs with Pde-2A as a Target
- Table 17: Drugs with Pde-5A as a Target
- Table 18: Drugs with Prkcb-1 as a Target
- Table 19: Drugs with Srd-5A1 as a Target
- Table 20: Drugs with Top-1 as a Target
- Table 21: Drugs with Top-2A as a Target
- Table 22: Drugs with Top-2A as a Target
- Table 23: Drugs with p53 protein as a Target
- Table 24: Breast Cancer Targets in Apoptopic Drug Development
- Table 25: Leukemia Targets in Apoptopic Drug Development
- Table 26: Lung Cancer Targets in Apoptopic Drug Development
- Table 27: Lymhoma Targets in Apoptopic Drug Development
- Table 28: Prostate Cancer Targets in Apoptopic Drug Development
- Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
- Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
- Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic
Drugs
- Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for
Breast Cancer
- Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for
Leukemia
- Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for
Lung Cancer
- Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for
Lymphoma
- Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for
Prostate Cancer
- Table 37: Overview of Targets in Commercial Development
- Table 38: Cyclin-dependent Kinase Targets in Development
- Table 39: Aurora Kinase Targets in Development
- Table 40: Cell Cycle Checkpoint Targets in Development
- Table 41: Epidermal Growth Factor Receptor Targets in Development
- Table 42: FMS-like tyrosine kinases and their Synonyms
- Table 43: Fms-related Tyrosine Kinase Targets in Development
- Table 44: Platelet-derived Growth Factor Receptor Targets in Development
- Table 45: Kinase Insert Domain Targets in Development
- Table 46: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
- Table 47: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
- Table 48: Serine/Threonine Kinase Inhibitors in Development
- Table 49: Protein Kinase Targets in Clinical Trials for Breast Cancer
- Table 50: Protein Kinase Targets in Clinical Trials for Prostate Cancer
- Table 51: Protein Kinase Targets in Clinical Trials for Lung Cancer
- Table 52: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
- Table 53: Protein Kinase Targets in Clinical Trials for Leukemia
- Table 54: Protein Kinase Targets in Clinical Trials for Melanoma
- Table 55: Protein Kinase Targets in Clinical Trials for Lymphoma
- Table 56: Drugs in Therapy - Mechanism & Targets
- Table 57: Current and Developmental History of PKI Drugs in Therapy
- Table 58: Approvals: Indications & Markets
- Table 59: Top 10 Drugs in Terms of Number of Clinical Trials
- Table 60: List of Cancer Indications Targeted by Protein Kinase Inhibitors
- Table 61: PKI Drugs in Development for Breast Cancer
- Table 62: PKI Drugs in Development for Prostate Cancer
- Table 63: PKI Drugs in Development for Lung Cancer
- Table 64: PKI Drugs in Development for Colorectal Cancer
- Table 65: PKI Drugs in Development for Leukemia
- Table 66: PKI Drugs in Development for Melanoma
- Table 67: PKI Drugs in Development for Lymphoma
- Table 68: Top 10's Anti-angiogenic and Vascular Targeting Pipeline Drugs
- Table 69: Deals & Alliances in 2005
- Table 70: Deals & Alliances in 2004
- Table 71: Deals & Alliances in 2003
- Table 72: Companies with Cancer Anti-angiogenic Drugs on the Market
- Table 73: 2006 Q2 Sales Revlimid and Thalomid
- Table 74: 2006 Q2 Sales of Avastin
- Table 75: List of 75 Known Targets in Ant-angiogenis and Vascular
Targeting in Drug Development
- Table 76: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
- Table 77: Drugs with Epidermal Growth Factor Receptor as a Target
- Table 78: Drugs with FMS-related Tyrosine Kinase 1 as a Target
- Table 79: Drugs with FMS-related Tyrosine Kinase 4 as a Target
- Table 80: Drugs with Kinase Insert Domain Receptor as a Target
- Table 81: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
- Table 82: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
- Table 83: Drugs with Patelet-Derived Growth Factor Receptor, alpha
Polypeptide as a Target
- Table 84: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a
Target
- Table 85: Drugs with Protein Kinase C, beta 1 as a Target
- Table 86: Drugs with Ret Proto-Oncogene as a Target
- Table 87: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene
Homolog as a Target
- Table 88: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a
Target
- Table 89: Drugs with Vascular Endothelial Growth Factor as a Target
- Table 90: Breast Cancer Targets in Anti-Angiogenic Drug Development
- Table 91: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
- Table 92: Lung Cancer Targets in Anti-Angiogenic Drug Development
- Table 93: Prostate Cancer Targets in Anti-Angiogenic Drug Development
- Table 94: Renal Cancer Targets in Anti-Angiogenic Drug Development
- Table 95: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular
Targeting Cancer Drugs
- Table 96: Recent Ceased or Discountinued Phase I to Phase III
Anti-angiogenic and Vascular Targeting Drugs
- Table 97: Overview of Drugs in Phase III Clinical Development
- Table 98: List of Phase I to Phase III Anti-Angiogenesis and Vascular
Targeting Agents in Development for Breast Cancer
- Table 99: List of Phase I to Phase III Anti-Angiogenesis and Vascular
Targeting Agents in Development for Colorectal Cancer
- Table 100: List of Phase I to Phase III Anti-Angiogenesis and Vascular
Targeting Agents in Development for Lung Cancer
- Table 101: List of Phase I to Phase III Anti-Angiogenesis and Vascular
Targeting Agents in Development for Prostate Cancer
- Table 102: List of Phase I to Phase III Anti-Angiogenesis and Vascular
Targeting Agents in Development for Renal Cancer
- Table 103: Summary of Strategies Enhancing Antibody Function
- Table 104: Companies with Cancer Vaccine Drugs on Market
- Table 105: Antigen Classification
- Table 106: Platforms Used to Improve Antigen Presentation
- Table 107: Cancer Vaccines in Clinical Trials in Combination with
Interleukin-2
- Table 108: Adjuvants in Cancer Vaccines
- Table 109: Synthetic Delivery Systems Deployed in Cancer in General and
Cancer Vaccines in Particular
- Table 110: Potential Advantages in Local, Controlled-Release for
Therapeutic Antibodies
- Table 111: Drug Delivery Companies with Cancer Focus
- Table 112: FDA Approved Polymer-based Drug Delivery Systems for Cancer
- Table 113: Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
- Table 114: Discountinued Phase I to Phase III Cancer Vaccine Drugs
- Table 115: List of Phase I to Phase III Cancer Vaccines in Development for
Melanoma
- Table 116: List of Phase I to Phase III Cancer Vaccines in Development for
Breast Cancer
- Table 117: List of Phase I to Phase III Cancer Vaccines in Development for
Prostate Cancer
- Table 118: List of Phase I to Phase III Cancer Vaccines in Development for
Lung Cancer
- Table 119: List of Phase I to Phase III Cancer Vaccines in Development for
Colorectal Cancer
- Table 120: List of Phase I to Phase III Cancer Vaccines in Development for
Cervical Cancer
- Table 121: Antibody Therapeutics in Prostate Cancer
- Table 122: Antibody Therapeutics in Breast Cancer
- Table 123: Antibody Therapeutics in Colorectal Cancer
- Table 124: Antibody Therapeutics in Melanoma
- Table 125: Antibody Therapeutics in Hematological Cancer
- Table 126: MDX-010's Collaborative History and Landscape
|
